Mainz Biomed NV (NASDAQ:QUCY) Short Interest Up 75.8% in June

Mainz Biomed NV (NASDAQ:QUCY) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 3,367,490 shares, a growth of 75.8% from the June 15th total of 1,915,904 shares. Currently, 23.7% of the shares of the stock are short sold. Based on an average daily volume of 8,070,542 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Weiss Ratings upgraded Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. Wall Street Zen raised Mainz Biomed to a “hold” rating in a research note on Saturday, June 6th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Mainz Biomed Trading Down 3.3%

Shares of NASDAQ:QUCY opened at $1.19 on Friday. The company has a market cap of $17.45 million, a P/E ratio of -0.02 and a beta of 2.28. Mainz Biomed has a 12 month low of $0.30 and a 12 month high of $4.93. The firm has a 50-day simple moving average of $1.96.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.